TITLE

Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients

AUTHOR(S)

Espíndola, Milena S.; Lima, Leonardo J. G.; Soares, Luana S.; Cacemiro, Maira C.; Zambuzi, Fabiana A.; de Souza Gomes, Matheus; Amaral, Laurence R.; Bollela, Valdes R.; Martins-Filho, Olindo A.; Frantz, Fabiani G.

PUB. DATE

December 2015

SOURCE

PLoS ONE;12/18/2015, Vol. 10 Issue 12, p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological profile of patients under distinct HAART regimens. This work aimed to investigate the differences in the immunological pattern of HIV-1+ patients under the first- or second-line HAART in Brazil. Methods: CD4+ T cell counts, Viral load, and plasma concentration of sCD14, sCD163, MCP-1, RANTES, IP-10, IL-1β, IL-6, TNF-α, IL-12, IFN-α, IFN-γ, IL-4, IL-5, and IL-10 were assessed for immunological characterization of the following clinical groups: Non-infected individuals (NI; n = 66), HIV-1+ untreated (HIV; n = 46), HIV-1+ treated with first-line HAART (HAART 1; n = 15); and HIV-1+ treated with second-line HAART (HAART 2; n = 15). Results: We found that the immunological biosignature pattern of HAART 1 is similar to that of NI individuals, especially in patients presenting slow progression of the disease, while patients under HAART 2 remain in a moderate inflammatory state, which is similar to that of untreated HIV patients pattern. Network correlations revealed that differences in IP-10, TNF-α, IL-6, IFN-α, and IL-10 interactions were primordial in HIV disease and treatment. Heat map and decision tree analysis identified that IP-10>TNF-α>IFN-α were the best respective HAART segregation biomarkers. Conclusion: HIV patients in different HAART regimens develop distinct immunological biosignature, introducing a novel perspective into disease outcome and potential new therapies that consider HAART patients as a heterogeneous group.

ACCESSION #

111828724

 

Related Articles

• No Association of Cryptococcal Antigenemia with Poor Outcomes among Antiretroviral Therapy-Experienced HIV-Infected Patients in Addis Ababa, Ethiopia. Smitson, Christopher C.; Tenna, Admasu; Tsegaye, Mulugeta; Alemu, Abere S.; Fekade, Daniel; Aseffa, Abraham; Blumberg, Henry M.; Kempker, Russell R. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

  Introduction: There are limited data on clinical outcomes of ART-experienced patients with cryptococcal antigenemia. We assessed clinical outcomes of a predominantly asymptomatic, ART-experienced cohort of HIV+ patients previously found to have a high (8.4%) prevalence of cryptococcal...

• The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey. Sherer Jr., Renslow D.; Fath, Michael J.; Da Silva, Barbara A.; Nicolau, Ana-Maria; Miller, Nancy L. // AIDS Patient Care & STDs;Dec2005, Vol. 19 Issue 12, p794 

  Patients who were receiving or had received antiretroviral therapy (ART) participated in 45-minute telephone interviews to evaluate the importance of major treatment attributes. A Likert scale was used to quantify and rate the importance of 9 ART attributes. Trade-off exercises allowed...

• Factors Associated with Late Antiretroviral Therapy Initiation among Adults in Mozambique. Lahuerta, Maria; Lima, Josue; Nuwagaba-Biribonwoha, Harriet; Okamura, Mie; Alvim, Maria Fernanda; Fernandes, Rufino; Assan, Americo; Hoos, David; Elul, Batya; El-Sadr, Wafaa M.; Nash, Denis // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

  Background: Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes, and onward transmission. Methods: To evaluate...

• Low-Level Viremia and Proviral DNA Impede Immune Reconstitution in HIV-1--Infected Patients Receiving Highly Active Antiretroviral Therapy. Ostrowski, Sisse R.; Katzenstein, Terese L.; Thim, Per T.; Pedersen, Bente K.; Gerstoft, Jan; Ullum, Henrik // Journal of Infectious Diseases;2/1/2005, Vol. 191 Issue 3, p348 

  Background. Immunological and virological consequences of low-level viremia in human immunodeficiency virus (HIV) type 1-infected patients receiving highly active antiretroviral therapy (HAART) remain to be determined. Methods. For 24 months, 101 HAART-treated, HIV-1-infected patients with HIV...

• Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy. Winston, Alan; Arenas-Pinto, Alejandro; Stöhr, Wolfgang; Fisher, Martin; Orkin, Chloe M.; Aderogba, Kazeem; De Burgh-Thomas, Andrew; O'Farrell, Nigel; Lacey, Charles JN.; Leen, Clifford; Dunn, David; Paton, Nicholas I. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

  Objective: To describe factors associated with neurocognitive (NC) function in HIV-positive patients on stable combination antiretroviral therapy. Design: We undertook a cross-sectional analysis assessing NC data obtained at baseline in patients entering the...

• Prevalence and Clinical Implications of Interactive Toxicity Beliefs Regarding Mixing Alcohol and Antiretroviral Therapies among People Living with HIV/AIDS. Kalichman, Seth C.; Amaral, Christina M.; White, Denise; Swetsze, Connie; Pope, Howard; Kalichman, Moira O.; Cherry, Chauncey; Eaton, Lisa // AIDS Patient Care & STDs;Jun2009, Vol. 23 Issue 6, p449 

  Alcohol use is a barrier to medication adherence. Beyond the cognitive effects of intoxication, people living with HIV/AIDS who believe that alcohol should not be mixed with their medications may temporarily stop taking medications when drinking. To examine the effects of alcohol-treatment...

• Contributions of Escherichia coli to Diarrhoea among HIV/AIDS Patients at a Hospital in Tropical West Africa. Tyodugh, Esther D.; Emanghe, Ubleni U.; Jombo, Godwin T.; Abraham, Ella B. // British Microbiology Research Journal;2012, Vol. 2 Issue 3, p175 

  Aims: To ascertain the contributions of Escherichia coli to diarrhea among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in a HIV endemic community. Study Design: Hospital based cross-sectional study. Place and Duration of Study: Mkar Christian...

• Use of complementary therapies to treat patients with HIV/AIDS. Palmer, Richard // Nursing Standard;8/20/2008, Vol. 22 Issue 50, p35 

  This article investigates the use of complementary and alternative medicine (CAM) in people living with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Since the beginning of the HIV/AIDS pandemic people living with HIV/AIDS have turned to CAM, either to...

• HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Manfredi, Roberto; Sabbatani, Sergio; Fasulo, Giovanni // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p501 

  An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described. An international literature search allowed...

Read the Article